Lineage Cell Therapeutics Statistics Share Statistics Lineage Cell Therapeutics has 228.36M
shares outstanding. The number of shares has increased by 20.93%
in one year.
Shares Outstanding 228.36M Shares Change (YoY) 20.93% Shares Change (QoQ) 0% Owned by Institutions (%) 48.37% Shares Floating 227.36M Failed to Deliver (FTD) Shares 111,588 FTD / Avg. Volume 4.66%
Short Selling Information The latest short interest is 28.09M, so 12.3% of the outstanding
shares have been sold short.
Short Interest 28.09M Short % of Shares Out 12.3% Short % of Float 21.96% Short Ratio (days to cover) 16.17
Valuation Ratios The PE ratio is -5.41 and the forward
PE ratio is -19.7.
Lineage Cell Therapeutics's PEG ratio is
0.22.
PE Ratio -5.41 Forward PE -19.7 PS Ratio 10.59 Forward PS 8.5 PB Ratio 1.28 P/FCF Ratio -4.25 PEG Ratio 0.22
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Lineage Cell Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.65,
with a Debt / Equity ratio of 0.03.
Current Ratio 3.65 Quick Ratio 3.65 Debt / Equity 0.03 Debt / EBITDA -0.12 Debt / FCF -0.11 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $135.7K Profits Per Employee $-265.84K Employee Count 70 Asset Turnover 0.08 Inventory Turnover n/a
Taxes Income Tax 27K Effective Tax Rate -0.15%
Stock Price Statistics The stock price has increased by 19.05% in the
last 52 weeks. The beta is 1.66, so Lineage Cell Therapeutics's
price volatility has been higher than the market average.
Beta 1.66 52-Week Price Change 19.05% 50-Day Moving Average 0.93 200-Day Moving Average 0.68 Relative Strength Index (RSI) 49.86 Average Volume (20 Days) 2,395,243
Income Statement In the last 12 months, Lineage Cell Therapeutics had revenue of 9.5M
and earned -18.61M
in profits. Earnings per share was -0.09.
Revenue 9.5M Gross Profit 9.16M Operating Income -21.48M Net Income -18.61M EBITDA -20.87M EBIT -21.48M Earnings Per Share (EPS) -0.09
Full Income Statement Balance Sheet The company has 45.79M in cash and 2.51M in
debt, giving a net cash position of 43.27M.
Cash & Cash Equivalents 45.79M Total Debt 2.51M Net Cash 43.27M Retained Earnings -403.46M Total Assets 111.75M Working Capital 36.9M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -23.09M
and capital expenditures -565K, giving a free cash flow of -23.66M.
Operating Cash Flow -23.09M Capital Expenditures -565K Free Cash Flow -23.66M FCF Per Share -0.12
Full Cash Flow Statement Margins Gross margin is 96.48%, with operating and profit margins of -226.11% and -195.9%.
Gross Margin 96.48% Operating Margin -226.11% Pretax Margin -195.62% Profit Margin -195.9% EBITDA Margin -219.7% EBIT Margin -226.11% FCF Margin -249.05%
Dividends & Yields LCTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LCTX is $3,
which is 200% higher than the current price. The consensus rating is "Buy".
Price Target $3 Price Target Difference 200% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 31, 1997. It was a
forward
split with a ratio of 3:1.
Last Split Date Oct 31, 1997 Split Type forward Split Ratio 3:1
Scores Altman Z-Score -1.3 Piotroski F-Score 3
